---
document_datetime: 2025-12-02 06:21:22
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/xiapex.html
document_name: xiapex.html
version: success
processing_time: 0.1124358
conversion_datetime: 2025-12-28 15:47:33.584299
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Xiapex

[RSS](/en/individual-human-medicine.xml/65712)

##### Withdrawn

This medicine's authorisation has been withdrawn

collagenase Clostridium histolyticum Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Xiapex](#news-on)
- [More information on Xiapex](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 5 December 2019, the European Commission withdrew the marketing authorisation for Xiapex (collagenase Clostridium histolyticum) in the European Union (EU). The withdrawal is effective as of 1 March 2020. The withdrawal was at the request of the marketing authorisation holder, Swedish Orphan Biovitrum AB (publ), which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Xiapex was granted marketing authorisation in the EU on 28 February 2011 for treatment of Dupuytren's contracture/ Peyronie's disease in adult patients.

The European Public Assessment Report (EPAR) for Xiapex is updated to indicate that the marketing authorisation is no longer valid.

Xiapex : EPAR - Summary for the public

Reference Number: EMEA/H/C/002048

English (EN) (671.95 KB - PDF)

**First published:** 14/03/2011

**Last updated:** 02/03/2020

[View](/en/documents/overview/xiapex-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-955)

български (BG) (791.48 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/bg/documents/overview/xiapex-epar-summary-public_bg.pdf)

español (ES) (672 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/es/documents/overview/xiapex-epar-summary-public_es.pdf)

čeština (CS) (748.27 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/cs/documents/overview/xiapex-epar-summary-public_cs.pdf)

dansk (DA) (665.44 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/da/documents/overview/xiapex-epar-summary-public_da.pdf)

Deutsch (DE) (674.54 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/de/documents/overview/xiapex-epar-summary-public_de.pdf)

eesti keel (ET) (665.96 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/et/documents/overview/xiapex-epar-summary-public_et.pdf)

ελληνικά (EL) (799.95 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/el/documents/overview/xiapex-epar-summary-public_el.pdf)

français (FR) (673.65 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/fr/documents/overview/xiapex-epar-summary-public_fr.pdf)

hrvatski (HR) (691.54 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/hr/documents/overview/xiapex-epar-summary-public_hr.pdf)

italiano (IT) (670.46 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/it/documents/overview/xiapex-epar-summary-public_it.pdf)

latviešu valoda (LV) (752.46 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/lv/documents/overview/xiapex-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (697.65 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/lt/documents/overview/xiapex-epar-summary-public_lt.pdf)

magyar (HU) (741.89 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/hu/documents/overview/xiapex-epar-summary-public_hu.pdf)

Malti (MT) (751.91 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/mt/documents/overview/xiapex-epar-summary-public_mt.pdf)

Nederlands (NL) (670.19 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/nl/documents/overview/xiapex-epar-summary-public_nl.pdf)

polski (PL) (762.78 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/pl/documents/overview/xiapex-epar-summary-public_pl.pdf)

português (PT) (672.18 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/pt/documents/overview/xiapex-epar-summary-public_pt.pdf)

română (RO) (700.68 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/ro/documents/overview/xiapex-epar-summary-public_ro.pdf)

slovenčina (SK) (747.28 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/sk/documents/overview/xiapex-epar-summary-public_sk.pdf)

slovenščina (SL) (737.49 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/sl/documents/overview/xiapex-epar-summary-public_sl.pdf)

Suomi (FI) (666.94 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/fi/documents/overview/xiapex-epar-summary-public_fi.pdf)

svenska (SV) (667.85 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/sv/documents/overview/xiapex-epar-summary-public_sv.pdf)

## Product information

Xiapex : EPAR - Product Information

English (EN) (1.56 MB - PDF)

**First published:** 14/03/2011

**Last updated:** 02/03/2020

[View](/en/documents/product-information/xiapex-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-984)

български (BG) (3.25 MB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/bg/documents/product-information/xiapex-epar-product-information_bg.pdf)

español (ES) (1.56 MB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/es/documents/product-information/xiapex-epar-product-information_es.pdf)

čeština (CS) (2.67 MB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/cs/documents/product-information/xiapex-epar-product-information_cs.pdf)

dansk (DA) (1.59 MB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/da/documents/product-information/xiapex-epar-product-information_da.pdf)

Deutsch (DE) (1.63 MB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/de/documents/product-information/xiapex-epar-product-information_de.pdf)

eesti keel (ET) (1.52 MB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/et/documents/product-information/xiapex-epar-product-information_et.pdf)

ελληνικά (EL) (3.26 MB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/el/documents/product-information/xiapex-epar-product-information_el.pdf)

français (FR) (1.66 MB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/fr/documents/product-information/xiapex-epar-product-information_fr.pdf)

hrvatski (HR) (1.69 MB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/hr/documents/product-information/xiapex-epar-product-information_hr.pdf)

íslenska (IS) (1.54 MB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/is/documents/product-information/xiapex-epar-product-information_is.pdf)

italiano (IT) (1.66 MB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/it/documents/product-information/xiapex-epar-product-information_it.pdf)

latviešu valoda (LV) (2.77 MB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/lv/documents/product-information/xiapex-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.89 MB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/lt/documents/product-information/xiapex-epar-product-information_lt.pdf)

magyar (HU) (2.63 MB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/hu/documents/product-information/xiapex-epar-product-information_hu.pdf)

Malti (MT) (2.8 MB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/mt/documents/product-information/xiapex-epar-product-information_mt.pdf)

Nederlands (NL) (1.57 MB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/nl/documents/product-information/xiapex-epar-product-information_nl.pdf)

norsk (NO) (1.76 MB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/no/documents/product-information/xiapex-epar-product-information_no.pdf)

polski (PL) (2.77 MB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/pl/documents/product-information/xiapex-epar-product-information_pl.pdf)

português (PT) (1.61 MB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/pt/documents/product-information/xiapex-epar-product-information_pt.pdf)

română (RO) (1.89 MB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/ro/documents/product-information/xiapex-epar-product-information_ro.pdf)

slovenčina (SK) (2.69 MB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/sk/documents/product-information/xiapex-epar-product-information_sk.pdf)

slovenščina (SL) (2.57 MB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/sl/documents/product-information/xiapex-epar-product-information_sl.pdf)

Suomi (FI) (1.59 MB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/fi/documents/product-information/xiapex-epar-product-information_fi.pdf)

svenska (SV) (1.57 MB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/sv/documents/product-information/xiapex-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** PSUSA/00000871/201902 28/11/2019

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Xiapex : EPAR - All Authorised presentations

English (EN) (574.28 KB - PDF)

**First published:** 14/03/2011

**Last updated:** 02/03/2020

[View](/en/documents/all-authorised-presentations/xiapex-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-259)

български (BG) (625.92 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/bg/documents/all-authorised-presentations/xiapex-epar-all-authorised-presentations_bg.pdf)

español (ES) (574.39 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/es/documents/all-authorised-presentations/xiapex-epar-all-authorised-presentations_es.pdf)

čeština (CS) (617.94 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/cs/documents/all-authorised-presentations/xiapex-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (574.33 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/da/documents/all-authorised-presentations/xiapex-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (574.42 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/de/documents/all-authorised-presentations/xiapex-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (575.26 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/et/documents/all-authorised-presentations/xiapex-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (625.22 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/el/documents/all-authorised-presentations/xiapex-epar-all-authorised-presentations_el.pdf)

français (FR) (572.88 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/fr/documents/all-authorised-presentations/xiapex-epar-all-authorised-presentations_fr.pdf)

íslenska (IS) (574.28 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/is/documents/all-authorised-presentations/xiapex-epar-all-authorised-presentations_is.pdf)

italiano (IT) (574.27 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/it/documents/all-authorised-presentations/xiapex-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (620.18 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/lv/documents/all-authorised-presentations/xiapex-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (602.55 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/lt/documents/all-authorised-presentations/xiapex-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (602.29 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/hu/documents/all-authorised-presentations/xiapex-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (617.95 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/mt/documents/all-authorised-presentations/xiapex-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (574.32 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/nl/documents/all-authorised-presentations/xiapex-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (597.86 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/no/documents/all-authorised-presentations/xiapex-epar-all-authorised-presentations_no.pdf)

polski (PL) (618.66 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/pl/documents/all-authorised-presentations/xiapex-epar-all-authorised-presentations_pl.pdf)

português (PT) (572.89 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/pt/documents/all-authorised-presentations/xiapex-epar-all-authorised-presentations_pt.pdf)

română (RO) (602.54 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/ro/documents/all-authorised-presentations/xiapex-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (618.15 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/sk/documents/all-authorised-presentations/xiapex-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (589.17 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/sl/documents/all-authorised-presentations/xiapex-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (574.31 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/fi/documents/all-authorised-presentations/xiapex-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (574.35 KB - PDF)

**First published:**

14/03/2011

**Last updated:**

02/03/2020

[View](/sv/documents/all-authorised-presentations/xiapex-epar-all-authorised-presentations_sv.pdf)

Xiapex : EPAR - Conditions imposed on member states for safe and effective use - Annex IV

English (EN) (831.5 KB - PDF)

**First published:** 14/03/2011

**Last updated:** 02/03/2020

[View](/en/documents/conditions-member-states/xiapex-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_en.pdf)

## Product details

Name of medicine Xiapex Active substance collagenase Clostridium histolyticum International non-proprietary name (INN) or common name collagenase Clostridium histolyticum Therapeutic area (MeSH) Dupuytren Contracture Anatomical therapeutic chemical (ATC) code M09AB02

### Pharmacotherapeutic group

Other drugs for disorders of the musculo-skeletal system

### Therapeutic indication

- The treatment of Dupuytren's contracture in adult patients with a palpable cord.
- The treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.

## Authorisation details

EMA product number EMEA/H/C/002048 Marketing authorisation holder

Swedish Orphan Biovitrum AB

Tomtebodavagen 23A

Marketing authorisation issued 28/02/2011 Revision 20

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Xiapex : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (1.71 MB - PDF)

**First published:** 28/02/2013

**Last updated:** 02/03/2020

[View](/en/documents/procedural-steps-after/xiapex-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Xiapex-H-C-PSUSA-871-201902 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/694468/2019

English (EN) (699.11 KB - PDF)

**First published:** 10/01/2020

**Last updated:** 02/03/2020

[View](/en/documents/scientific-conclusion/xiapex-h-c-psusa-871-201902-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Xiapex-H-C-PSUSA-871-201702 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/787779/2017

English (EN) (650.75 KB - PDF)

**First published:** 12/12/2017

**Last updated:** 02/03/2020

[View](/en/documents/scientific-conclusion/xiapex-h-c-psusa-871-201702-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Xiapex-H-C-PSUSA-00000871-201502 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/816625/2015

English (EN) (625.11 KB - PDF)

**First published:** 21/12/2015

**Last updated:** 02/03/2020

[View](/en/documents/scientific-conclusion/xiapex-h-c-psusa-00000871-201502-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Xiapex-H-C-PSUSA-0871-201402 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/207618/2015

English (EN) (639.39 KB - PDF)

**First published:** 26/06/2015

**Last updated:** 02/03/2020

[View](/en/documents/scientific-conclusion/xiapex-h-c-psusa-0871-201402-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Xiapex-H-C-2048-II-0044 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/349968/2015

English (EN) (8.67 MB - PDF)

**First published:** 26/05/2015

**Last updated:** 02/03/2020

[View](/en/documents/variation-report/xiapex-h-c-2048-ii-0044-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Xiapex

Adopted

Reference Number: EMA/CHMP/747440/2014

English (EN) (647.59 KB - PDF)

**First published:** 19/12/2014

**Last updated:** 02/03/2020

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xiapex_en.pdf)

## Initial marketing authorisation documents

Xiapex : EPAR - Public assessment report

Adopted

English (EN) (1.64 MB - PDF)

**First published:** 14/03/2011

**Last updated:** 02/03/2020

[View](/en/documents/assessment-report/xiapex-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Xiapex

Adopted

Reference Number: EMA/CHMP/773322/2010

English (EN) (625.76 KB - PDF)

**First published:** 17/12/2010

**Last updated:** 02/03/2020

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-xiapex_en.pdf)

#### News on Xiapex

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 December 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-december-2014) 19/12/2014

#### More information on Xiapex

- [Effectiveness of Xiapex® educational material for healthcare professionals in the treatment of Peyronie's disease - a non-interventional post-authorization safety study (Sobi.Xiapex-PASS01) - post-authorisation study](https://catalogues.ema.europa.eu/study/32787)
- [Effectiveness of Xiapex® educational material for healthcare professionals in the treatment of Peyronie's disease - a non-interventional postauthorization safety study (201954) - post-authorisation study](https://catalogues.ema.europa.eu/study/42102)
- [Effectiveness of Xiapex® educational material for healthcare professionals in the treatment of Dupuytren's contracture - a non-interventional post-authorization safety study - post-authorisation study](https://catalogues.ema.europa.eu/study/40919)

**This page was last updated on** 02/03/2020

## Share this page

[Back to top](#main-content)